JP2019524856A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524856A5 JP2019524856A5 JP2019510843A JP2019510843A JP2019524856A5 JP 2019524856 A5 JP2019524856 A5 JP 2019524856A5 JP 2019510843 A JP2019510843 A JP 2019510843A JP 2019510843 A JP2019510843 A JP 2019510843A JP 2019524856 A5 JP2019524856 A5 JP 2019524856A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- disease
- neurodegenerative disease
- nicotinamide riboside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378053P | 2016-08-22 | 2016-08-22 | |
| US62/378,053 | 2016-08-22 | ||
| PCT/US2017/047979 WO2018039207A1 (en) | 2016-08-22 | 2017-08-22 | Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524856A JP2019524856A (ja) | 2019-09-05 |
| JP2019524856A5 true JP2019524856A5 (OSRAM) | 2020-10-01 |
| JP7132907B2 JP7132907B2 (ja) | 2022-09-07 |
Family
ID=61246253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019510843A Active JP7132907B2 (ja) | 2016-08-22 | 2017-08-22 | ニコチンアミドリボシド及びプテロスチルベン組成物及び神経変性障害の治療方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11260069B2 (OSRAM) |
| EP (1) | EP3500267A4 (OSRAM) |
| JP (1) | JP7132907B2 (OSRAM) |
| KR (1) | KR20190046895A (OSRAM) |
| CN (2) | CN115645432A (OSRAM) |
| AU (1) | AU2017316614B2 (OSRAM) |
| BR (1) | BR112019003579A2 (OSRAM) |
| CA (1) | CA3034673A1 (OSRAM) |
| MX (1) | MX2019002211A (OSRAM) |
| RU (1) | RU2019108100A (OSRAM) |
| WO (1) | WO2018039207A1 (OSRAM) |
| ZA (1) | ZA201901536B (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017316614B2 (en) | 2016-08-22 | 2023-06-15 | Elysium Health, Inc. | Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders |
| WO2018213715A1 (en) * | 2017-05-18 | 2018-11-22 | Elysium Health, Inc. | Methods and compositions for improving sleep |
| SG11201912267SA (en) | 2017-06-19 | 2020-01-30 | Gangadhara Ganapati | Nicotinamide riboside derivatives and their uses |
| CN111542312A (zh) * | 2017-07-28 | 2020-08-14 | 老龄化控制中心股份公司 | 预防和逆转衰老方面的组合物和方法 |
| WO2020081923A1 (en) * | 2018-10-19 | 2020-04-23 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 in combination with nad+ or a nad+ precursor |
| WO2020102326A1 (en) * | 2018-11-13 | 2020-05-22 | Elysium Health, Inc | Methods for determining and increasing nad levels |
| US11833167B2 (en) | 2018-12-17 | 2023-12-05 | Mitopower Llc | Nicotinyl riboside compounds and their uses |
| US12350283B2 (en) | 2019-02-26 | 2025-07-08 | Universitat De Valencia-Estudi General | Methods and compositions for treating motor neuron diseases |
| CN110812365A (zh) * | 2019-11-07 | 2020-02-21 | 明特奇点医疗科技（北京）有限公司 | 一种组合物及其制备方法与制剂 |
| CN111838669B (zh) * | 2020-08-07 | 2022-11-29 | 四川大学华西医院 | 治疗改善易损脏器的纳米组合物、制剂及制备方法和用途 |
| EP4079311B1 (en) * | 2021-04-20 | 2025-10-01 | Nuvamid SA | Nmn and derivatives for use in the treatment of depression and/or anxiety in patients having a form of parkinsonism |
| WO2022269064A1 (en) * | 2021-06-24 | 2022-12-29 | Vestlandets Innovasjonsselskap As (Vis) | Nad-augmentation therapy for parkinson's disease |
| FI4284387T3 (fi) * | 2021-06-24 | 2024-08-20 | Vestlandets Innovasjonsselskap As Vis | NAD-augmentaatiohoito Parkinsonin tautiin |
| EP4422644A4 (en) * | 2021-10-27 | 2025-08-27 | Elysium Health Inc | METHODS OF TREATING MENOPAUSAL SYNDROMES |
| CN116807985A (zh) * | 2023-06-20 | 2023-09-29 | 风火轮(上海)生物科技有限公司 | 一种烟酰胺核糖组合物及其制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006001982A2 (en) * | 2004-06-04 | 2006-01-05 | Washington University | Methods and compositions for treating neuropathies |
| EP1877054A2 (en) | 2005-03-30 | 2008-01-16 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
| US20090069444A1 (en) * | 2007-09-07 | 2009-03-12 | The United States Of America, As Represented By Th E Secretary Of Agriculture | Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration |
| US20090163580A1 (en) * | 2007-12-24 | 2009-06-25 | Natrol, Inc. | Anti-aging composition containing resveratrol and method of administration |
| WO2010095926A1 (en) * | 2009-02-20 | 2010-08-26 | N.V. Nutricia | Use of reveratrol for preserving cognitive functioning |
| EP2445488B1 (en) | 2009-06-22 | 2020-03-18 | Indus Biotech Private Limited | Process for obtaining purified pterostilbene and methods of use thereof |
| US8933217B2 (en) | 2009-07-24 | 2015-01-13 | Amazentis Sa | Compounds, compositions, and methods for protecting brain health in neurodegenerative disorders |
| US9439875B2 (en) | 2011-05-11 | 2016-09-13 | The United States Of America, As Represented By The Secretary Of Agriculture | Anxiolytic effect of pterostilbene |
| EP2574339A1 (de) | 2011-09-27 | 2013-04-03 | Johannes Huber | Pharmazeutisches Präparat zur Behandlung von NADH-bedingten Erkrankungen |
| US20130149277A1 (en) | 2011-12-13 | 2013-06-13 | Cliffstar Llc | Pterostilbene and pvp grape juice extract combination for treatment of metabolic, vascular, and neurodegenerative disorders |
| US20130296440A1 (en) * | 2012-05-01 | 2013-11-07 | ChromaDex Inc. | Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation |
| MX385305B (es) * | 2013-10-30 | 2025-03-18 | Chromadex Inc | Composiciones de ribósido de nicotinamida para uso tópico en el tratamiento de afecciones de la piel. |
| AU2015270130A1 (en) | 2014-06-02 | 2016-12-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Preparation and use of crystalline beta-D-nicotinamide riboside |
| WO2016122832A1 (en) | 2015-01-30 | 2016-08-04 | Natural Formulations | Compositions, therapeutic and prophylactic methods for treatment of neurodegenerative diseases and brain injuries |
| WO2016149277A1 (en) * | 2015-03-17 | 2016-09-22 | Specialty Nutrition Group, Inc. | Nutritional compositions to enhance mitochondrial energy production |
| AU2017316614B2 (en) | 2016-08-22 | 2023-06-15 | Elysium Health, Inc. | Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders |
-
2017
- 2017-08-22 AU AU2017316614A patent/AU2017316614B2/en active Active
- 2017-08-22 MX MX2019002211A patent/MX2019002211A/es unknown
- 2017-08-22 BR BR112019003579-6A patent/BR112019003579A2/pt not_active Application Discontinuation
- 2017-08-22 WO PCT/US2017/047979 patent/WO2018039207A1/en not_active Ceased
- 2017-08-22 EP EP17844270.3A patent/EP3500267A4/en active Pending
- 2017-08-22 KR KR1020197008293A patent/KR20190046895A/ko not_active Ceased
- 2017-08-22 CN CN202211250881.3A patent/CN115645432A/zh active Pending
- 2017-08-22 CN CN201780064669.9A patent/CN109982706A/zh active Pending
- 2017-08-22 JP JP2019510843A patent/JP7132907B2/ja active Active
- 2017-08-22 RU RU2019108100A patent/RU2019108100A/ru not_active Application Discontinuation
- 2017-08-22 CA CA3034673A patent/CA3034673A1/en active Pending
- 2017-08-22 US US16/327,651 patent/US11260069B2/en active Active
-
2019
- 2019-03-12 ZA ZA2019/01536A patent/ZA201901536B/en unknown
-
2022
- 2022-01-21 US US17/580,999 patent/US11998561B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524856A5 (OSRAM) | ||
| DiMascio et al. | A controlled trial of amantadine in drug-induced extrapyramidal disorders | |
| RU2019108100A (ru) | Композиции никотинамид рибозида и птеростильбена и методы лечения нейродегенеративных заболеваний | |
| US8609162B2 (en) | Integrated neuromodulation system for mood enhancement of a living human subject | |
| Bischoff | Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events | |
| CA2667924A1 (en) | The use of pramipexole or a salt thereof for the treatment of parkinson's disease | |
| JP2014508758A5 (OSRAM) | ||
| JP2013501805A5 (OSRAM) | ||
| JP2014503596A5 (OSRAM) | ||
| JP2019514990A5 (OSRAM) | ||
| JPWO2008090736A1 (ja) | アルツハイマー型認知症の予防及び治療のための医薬 | |
| JP2009502805A5 (OSRAM) | ||
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| JP2019507786A5 (OSRAM) | ||
| Nomoto et al. | A case of frontotemporal dementia with sexual disinhibition controlled by aripiprazole. | |
| Gulick | HIV treatment 2020: what will it look like? | |
| MX2022012693A (es) | Composicion que comprende metilfolato. | |
| Ravshanova et al. | Studies of acute toxicity of the drug" Analfenon" for use in tablet form | |
| Frampton | Oxycodone/naloxone PR: a review in severe refractory restless legs syndrome | |
| CN105451749A (zh) | 吸附雄蜂幼虫匀浆和维生素d3或d族维生素和/或其活性代谢物在病毒性疾病的预防和治疗中的应用 | |
| Cam et al. | Mania associated with quetiapine treatment | |
| Chaudhary et al. | A review on Parkinson’s disease: overview and management | |
| Latif et al. | Structured Education and Daily Reminders to Improve Medication Adherence in Tuberculosis Patients: A Case Study | |
| Roller et al. | Parkinsonism and parkinson's disease | |
| MX2024001230A (es) | Anticoncepcion oral con progestageno solo. |